Business Briefing: F.D.A. Clears Cheaper Version of Johnson & Johnson Biologic
Federal officials have approved a cheaper version of Johnson & Johnson’s blockbuster drug Remicade, a biotech medicine for inflammatory diseases.
Investing May Be Cheaper, but Fees Still Hurt
Expenses are shrinking, enabling many investors to keep more of their return dollars. But experts say the fees could, and should, be diminishing faster.